Related Experiment Video
Updated: May 17, 2026
07:30
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside.
Amanda C Peltier1, Peter D Donofrio
1Department of Neurology, Vanderbilt Medical Center, Medical Center North, Nashville, Tennessee 37232-2551, USA. amanda_c_peltier@vanderbilt.edu
Seminars in Neurology
|November 3, 2012
Summary
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a treatable autoimmune neuropathy. This review covers CIDP
Area of Science:
- Neurology
- Immunology
- Pathology
Background:
- Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common treatable chronic autoimmune neuropathy.
- Diagnostic criteria focus on identifying neurophysiologic hallmarks of acquired demyelination.
- Treatment options include corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg).
Purpose of the Study:
- To provide a comprehensive overview of Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- To review the pathology, epidemiology, pathogenesis, diagnosis, and treatment of CIDP.
Main Methods:
- Literature review of existing studies and clinical guidelines on CIDP.
- Synthesis of information on diagnostic criteria and treatment efficacy.
- Description of the underlying pathology and pathogenesis.
Main Results:
- CIDP is characterized by acquired demyelination.
- Established diagnostic criteria aid in identifying the condition.
- Corticosteroids, plasma exchange, and IVIg are primary treatment modalities.
Conclusions:
- CIDP requires accurate diagnosis based on neurophysiologic findings.
- Effective treatment strategies are available, with corticosteroids, plasma exchange, and IVIg showing the strongest evidence.
- Further understanding of CIDP's pathology and pathogenesis can inform future therapeutic approaches.
